Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Cerilliant
Julphar
Federal Trade Commission
Queensland Health
UBS
QuintilesIMS
Fish and Richardson
AstraZeneca
Deloitte

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,625,884

« Back to Dashboard

Which drugs does patent 7,625,884 protect, and when does it expire?


Patent 7,625,884 protects GIAZO and COLAZAL and is included in two NDAs. There has been one Paragraph IV challenge on Giazo.

Protection for COLAZAL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-four patent family members in eleven countries.

Summary for Patent: 7,625,884

Title:Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Abstract:A method of increasing the bioavailability of balsalazide by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of balsalazide in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.
Inventor(s): Johnson; Lorin (Palo Alto, CA)
Assignee: Salix Pharmaceuticals, Ltd (Morrisville, NC)
Application Number:11/877,589
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Valeant Pharms IntlGIAZObalsalazide disodiumTABLET;ORAL022205-001Feb 3, 2012ABRXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS
Valeant Pharms IntlCOLAZALbalsalazide disodiumCAPSULE;ORAL020610-001Jul 18, 2000ABRXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,625,884

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,452,872Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives► Subscribe
9,192,616Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives► Subscribe
8,921,344Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,625,884

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2006282865► Subscribe
Australia2007322362► Subscribe
BrazilPI0615195► Subscribe
BrazilPI0717859► Subscribe
Canada2620091► Subscribe
Canada2668441► Subscribe
Canada2816276► Subscribe
China101247812► Subscribe
China101610670► Subscribe
China102670626► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Chubb
Federal Trade Commission
UBS
Mallinckrodt
Moodys
Chinese Patent Office
Fuji
Teva
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot